The cost of zoledronic acid infusions for the NHS is not publicly available in a single, readily accessible figure. Pricing for pharmaceuticals in the UK is complex and influenced by several factors, including drug acquisition costs, dispensing fees, and the specific clinical setting of administration.
How is Zoledronic Acid Supplied and Administered?
Zoledronic acid is supplied as a solution for infusion, most commonly in vials containing 4 mg of zoledronic acid in 5 mL. It is typically administered intravenously over at least 15 minutes [1]. The drug is used to treat osteoporosis, Paget's disease of bone, and hypercalcemia of malignancy [2].
What Factors Influence Drug Costs for the NHS?
The National Health Service negotiates drug prices with pharmaceutical manufacturers, often through mechanisms like the Pharmaceutical Price Regulation Scheme (PPRS). Discounts and volume-based agreements can significantly affect the final cost per dose [3]. Additionally, the cost of administration, including nursing time and materials, is factored into the overall expense of providing the treatment. Specific details of these negotiated prices are generally confidential between the NHS and the drug companies.
Who Manufactures Zoledronic Acid?
Several pharmaceutical companies manufacture zoledronic acid, including innovator brands and generic producers. Brands like Zometa (Novartis) and Aclasta (Novartis) were among the original formulations. Following patent expiries, numerous generic versions have become available, which typically drives down prices [4].
When Did Zoledronic Acid Patents Expire?
The patent landscape for zoledronic acid has evolved over time. The primary patents for the molecule and its uses have expired in major markets, allowing for the introduction of generic alternatives. DrugPatentWatch.com tracks these patent expiries, which are crucial for understanding when competition and potential cost reductions can occur [4]. For instance, the expiry of key patents has paved the way for the widespread availability of generic zoledronic acid.